Pharmacogenetics of antiretroviral therapy: genetic variation of response and toxicity.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Pharmacogenomics (London)

• Publication date

  2004-11-04

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1517/14622416.5.6.643PMID 15335286
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Transporters and renal drug elimination.

  2004cited by this paper
• A marker for Stevens–Johnson syndrome

  2004cited by this paper
• Pharmacogenomics of proton pump inhibitors.

  2004cited by this paper
• Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy.

  2004cited by this paper
• Reduction of mitochondrial DNA content and respiratory chain activity occurs in adipocytes within 6–12 months of commencing nucleoside reverse transcriptase inhibitor therapy

  2004cited by this paper
• Maternally inherited aminoglycoside-induced and nonsyndromic deafness is associated with the novel C1494T mutation in the mitochondrial 12S rRNA gene in a large Chinese family.

  2004cited by this paper
• Comparative genomic analysis, diversity and evolution of two KIR haplotypes A and B.

  2004cited by this paper
• Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors.

  2004cited by this paper
• Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant

  2004cited by this paper
• Effects of Purifying and Adaptive Selection on Regional Variation in Human mtDNA

  2004cited by this paper
• Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations.

  2004cited by this paper
• Serious Adverse Cutaneous and Hepatic Toxicities Associated With Nevirapine Use by Non–HIV-Infected Individuals

  2004cited by this paper
• Genetic variability in CYP3A5 and its possible consequences.

  2004cited by this paper
• Polymorphisms in Human MDR1 (P‐glycoprotein): Recent Advances and Clinical Relevance

  2004cited by this paper
• Accumulation of mitochondrial DNA mutations in human immunodeficiency virus-infected patients treated with nucleoside-analogue reverse-transcriptase inhibitors.

  2003cited by this paper
• Increased expression of TNF-alpha, IL-6, and IL-8 in HALS: implications for reduced adiponectin expression and plasma levels.

  2003cited by this paper
• Digoxin pharmacokinetics and MDR1 genetic polymorphisms

  2003cited by this paper
• Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy

  2003cited by this paper
• In polymorphic genomic regions indels cluster with nucleotide polymorphism: Quantum Genomics.

  2003cited by this paper
• Tumour necrosis factor-alpha gene -238G/A promoter polymorphism associated with a more rapid onset of lipodystrophy

  2003cited by this paper
• Hepatic CYP2B6 Expression: Gender and Ethnic Differences and Relationship to CYP2B6 Genotype and CAR (Constitutive Androstane Receptor) Expression

  2003cited by this paper
• Pharmacogenetics: a practical role in predicting antiretroviral drug toxicity?

  2003cited by this paper
• Studies of adipose tissue metabolism in human immunodeficiency virus-associated lipodystrophy.

  2003cited by this paper
• MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients

  2003cited by this paper
• Epidemiological risk factors for hypersensitivity reactions to abacavir *

  2003cited by this paper
• A Comprehensive Hepatic Safety Analysis of Nevirapine in Different Populations of HIV Infected Patients*

  2003cited by this paper
• Pharmacokinetic Drug Interactions with Nevirapine

  2003cited by this paper
• Thymidine analogue-sparing highly active antiretroviral therapy (HAART).

  2003cited by this paper
• Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein.

  2003cited by this paper
• Molecular aspects of drug recognition by specific T cells.

  2003cited by this paper
• Sequence variations of mitochondrial DNA and individual sensitivity to the ototoxic effect of cisplatin.

  2003cited by this paper
• Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir.

  2003cited by this paper
• Comparative sequencing of human and chimpanzee MHC class I regions unveils insertions/deletions as the major path to genomic divergence

  2003cited by this paper
• Characterization of a potential animal model of an idiosyncratic drug reaction: nevirapine-induced skin rash in the rat.

  2003cited by this paper
• Contribution of Nucleoside-Analogue Reverse Transcriptase Inhibitor Therapy to Lipoatrophy from the Population to the Cellular Level

  2002cited by this paper
• MDR1 genotype-related pharmacokinetics and pharmacodynamics.

  2002cited by this paper
• Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir.

  2002cited by this paper
• Risk factor analysis of hypersensitivity reactions to abacavir.

  2002cited by this paper
• Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.

  2002cited by this paper
• The Structure of Haplotype Blocks in the Human Genome

  2002cited by this paper
• Monitoring Adverse Drug Reactions to Sulfonamide Antibiotics in Human Immunodeficiency Virus–Infected Individuals

  2002cited by this paper
• Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.

  2002cited by this paper
• TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy.

  2002cited by this paper
• Mitochondrial Proliferation, Dna Depletion and Adipocyte Differentiation in Subcutaneous Adipose Tissue of HIV-Positive Haart Recipients

  2002cited by this paper
• Mitochondrial Dna Depletion and Respiratory Chain Enzyme Deficiencies are Present in Peripheral Blood Mononuclear Cells of HIV-Infected Patients with Haart-Related Lipodystrophy

  2002cited by this paper
• Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study.

  2002cited by this paper
• How many SNPs does a genome-wide haplotype map require?

  2002cited by this paper
• Covalent binding of the nitroso metabolite of sulfamethoxazole leads to toxicity and major histocompatibility complex-restricted antigen presentation.

  2002cited by this paper
• Thymic volume predicts long-term immune reconstitution in HIV-infected children treated with highly active antiretroviral therapy

  2002cited by this paper
• Abacavir hypersensitivity reaction.

  2002cited by this paper
• Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.

  2002cited by this paper
• TNF-α promoter region gene polymorphisms in HIV-positive patients with lipodystrophy

  2002cited by this paper
• Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study.

  2001cited by this paper
• High-resolution haplotype structure in the human genome

  2001cited by this paper
• An infectious transfer and expression system for genomic DNA loci in human and mouse cells

  2001cited by this paper
• Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients

  2001cited by this paper
• TNFα promoter region gene polymorphisms in carbamazepine-hypersensitive patients

  2001cited by this paper
• Molecular basis of ethnic differences in drug disposition and response.

  2001cited by this paper
• The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement.

  2001cited by this paper
• Nelfinavir Plasma Levels Under Twice-Daily and Three-Times-Daily Regimens: High Interpatient and Low Intrapatient Variability

  2001cited by this paper
• Hypersensitivity Related to Abacavir in Two Members of a Family

  2001cited by this paper
• Analysis of variation in plasma concentrations of nelfinavir and its active metabolite M8 in HIV-positive patients

  2001cited by this paper
• Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review.

  2001cited by this paper
• Delavirdine: clinical pharmacokinetics and drug interactions.

  2001cited by this paper
• Genetic susceptibility to adverse drug reactions.

  2001cited by this paper
• Clinical application of pharmacogenetics.

  2001cited by this paper
• Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus-infected patients with chronic liver disease.

  2000cited by this paper
• SNP profile within the human major histocompatibility complex reveals an extreme and interrupted level of nucleotide diversity.

  2000cited by this paper
• Fine localization of a major disease-susceptibility locus for diffuse panbronchiolitis.

  2000cited by this paper
• The predictive power of haplotypes in clinical response.

  2000cited by this paper
• Error in Medicine: What Have We Learned?

  2000cited by this paper
• Genotype and phenotype of cytochrome P450 2D6 in human immunodeficiency virus-positive patients and patients with acquired immunodeficiency syndrome

  2000cited by this paper
• MIC-A polymorphism in Japanese and a MIC-A-MIC-B null haplotype

  1999cited by this paper
• Genomics of the major histocompatibility complex: haplotypes, duplication, retroviruses and disease

  1999cited by this paper
• Pharmacokinetics and Potential Interactions Amongst Antiretroviral Agents Used To Treat Patients with HIV Infection

  1999cited by this paper
• Protease Inhibitors as Inhibitors of Human Cytochromes P450: High Risk Associated with Ritonavir

  1998cited by this paper
• Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.

  1998cited by this paper
• HLA-restricted, processing- and metabolism-independent pathway of drug recognition by human alpha beta T lymphocytes.

  1998cited by this paper
• Mitochondria alterations and dramatic tendency to undergo apoptosis in peripheral blood lymphocytes during acute HIV syndrome

  1997cited by this paper
• High IL-5 production by human drug-specific T cell clones.

  1997cited by this paper
• Direct, MHC-dependent presentation of the drug sulfamethoxazole to human alphabeta T cell clones.

  1997cited by this paper
• An approach to the localization of the susceptibility genes for generalized myasthenia gravis by mapping recombinant ancestral haplotypes

  1992cited by this paper
• Ancestral haplotypes reveal the role of the central MHC in the immunogenetics of IDDM

  1992cited by this paper
• Genetics of diabetes. Studies of MHC haplotypes by pulsed field gel electrophoresis.

  1991cited by this paper
• 5 Studies of MHC haplotypes by pulsed field gel electrophoresis

  1991cited by this paper
• Prevalence of adverse events associated with potent antiretroviral treatment : Swiss HIV Cohort Study

  year unknowncited by this paper

• Animal Models, Therapeutics, and Vaccine Approaches to Emerging and Re-Emerging Flaviviruses

  2024cites this paper
• Ethyl Gallate: Promising Cytoprotective against HIV-1-Induced Cytopathy and Antiretroviral-Induced Cytotoxicity

  2023cites this paper
• Nanomedicines encountering HIV dementia: A guiding star for neurotherapeutics

  2022cites this paper
• Cerebral Vascular Toxicity of Antiretroviral Therapy

  2019cites this paper
• Correlation between HIV-1 genotype and clinical progression in HIV/AIDS patients in Surabaya, Indonesia

  2018cites this paper
• Pharmacogenetic considerations for HIV treatment in different ethnicities: an update

  2017cites this paper
• A pharmacist's role in the individualization of treatment of HIV patients.

  2016cites this paper
• Management Strategies for Clopidogrel Hypersensitivity

  2015cites this paper
• Variation in ABCB1 and its effect on immune recovery with antiretrovirals

  2012influential citation
• [Pharmacogenetics of antiretroviral drugs].

  2012cites this paper
• Genome-wide association studies on HIV susceptibility, pathogenesis and pharmacogenomics

  2012cites this paper
• Plasma Drug Level Validates Self-Reported Adherence but Predicts Limited Specificity for Nonadherence to Antiretroviral Therapy

  2012cites this paper
• A Pharmacogenomical perspective in HIV/AIDS Therapies

  2012cites this paper
• Characterization of clopidogrel hypersensitivity reactions and management with oral steroids without clopidogrel discontinuation.

  2011cites this paper
• The influence of host genetic factors on HIV-1 infection

  2011cites this paper
• Similarities between the discovery and regulation of pharmaceuticals and pesticides: in support of a better understanding of the risks and benefits of each.

  2011cites this paper
• Pharmacogenomics of CYP3A: considerations for HIV treatment.

  2009cites this paper
• Personalizing antiretroviral therapy: is it a reality?

  2009cites this paper
• Nevirapine hypersensitivity reaction: will the real HLA please stand up?

  2009cites this paper
• [HLA-B*5701 and hypersensitivity reactions to abacavir. Study methods and clinical relevance].

  2008cites this paper
• Cytokine Profiling in Abacavir Hypersensitivity Patients

  2008influential citation
• Pharmacogenetic Issues in Biopharmaceutical Drug Development

  2008cites this paper
• Therapeutic drug monitoring in the management of HIV-infected patients.

  2008cites this paper
• HIV-Therapie mit dem Nukleosidanalogon Abacavir: Hypersensitivitätsreaktionen und HLA-B57-Status

  2008cites this paper
• A review of drug patch testing and implications for HIV clinicians

  2008cites this paper
• HLA-B*5701 y reaccin de hipersensibilidad a abacavir. Mtodos de estudio y relevancia clnica

  2008cites this paper
• Pharmacogenomics, toxicogenomics, and DNA polymerase gamma.

  2007cites this paper
• Management of antiretroviral treatment-related complications.

  2007cites this paper
• Advances in pharmacogenomics of antiretrovirals: an update.

  2007cites this paper
• Pharmacogenetics in HIV Clinical Practice

  2007cites this paper
• Nucleoside and nucleotide analogue reverse transcriptase inhibitor toxicity: how much longer must we wield the sword?

  2007cites this paper
• Pharmacogenetic Considerations in the Management of HIV Infection

  2007cites this paper
• Pharmacogenomics, Toxicogenomics, and DNA Polymerase γ

  2007cites this paper
• The Introduction of Pharmacogenetic Screening to HIV Clinical Practice – Potential Benefits and Challenges 13

  2007cites this paper
• Efavirenz and CYP2B6 polymorphism: implications for drug toxicity and resistance.

  2006cites this paper
• The pharmacogenetics of antiretroviral therapy

  2006cites this paper
• Predicting and diagnosing abacavir and nevirapine drug hypersensitivity: from bedside to bench and back again.

  2006cites this paper
• Copy number variants and pharmacogenomics.

  2006cites this paper
• Toxicité des antirétroviraux chez les patients co-infectés par les virus VIH et VHC

  2006cites this paper
• Influence of 516 G 1 T Polymorphisms at the Gene Encoding the CYP 450-2 B 6 Isoenzyme on Efavirenz Plasma Concentrations in HIV-Infected Subjects

  2005cites this paper
• Cell death in HIV dementia

  2005cites this paper
• A review of the aetiology of dyslipidaemia and hyperlipidaemia in patients with HIV

  2005cites this paper
• Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects.

  2005cites this paper
• Genetic diversity and new therapeutic concepts

  2005cites this paper
• Communication of pharmacogenetic research results to HIV-infected treated patients: standpoints of professionals and patients

  2005cites this paper